The present invention relates to anticancer therapy in patients bearing tumors overexpressing Trop-2, by means of drugs directed against a component of the signalling network of Trop-2, wherein said component is Akt. Trop-2 overexpression can also be exploited for the screening in vitro and in vivo of the anticancer activity of new compounds.
Use of Trop-2 as predictive marker of response to anti-tumor therapy based on inhibitors of AKT (European Patent)
Guerra EmanuelaPrimo
;
2013-01-01
Abstract
The present invention relates to anticancer therapy in patients bearing tumors overexpressing Trop-2, by means of drugs directed against a component of the signalling network of Trop-2, wherein said component is Akt. Trop-2 overexpression can also be exploited for the screening in vitro and in vivo of the anticancer activity of new compounds.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
